Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Savior LifetecROCO:4167 +0.77%70 Debt-to-Equity is 0.07 as of Jun. 2026, which is 76% below its 10-year median of 0.29. GuruFocus rates ROCO:4167 with a GF Score™ of 70/100 and a GF Value™ of NT$18.12 (Fairly Valued). The stock has 6 warning signs investors should review. Among 964 Biotechnology companies, Savior Lifetec ranks better than 64.83% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Savior Lifetec's Debt-to-Equity or its related term are showing as below:
ROCO:4167'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.29 Max: 0.9
Current: 0.07
During the past 13 years, the highest Debt-to-Equity Ratio of Savior Lifetec was 0.90. The lowest was 0.05. And the median was 0.29.
ROCO:4167's Debt-to-Equity is ranked better than 64.83% of 964
companies
in the Biotechnology industry
Industry Median: 0.155
vs ROCO:4167: 0.07
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Savior Lifetec Debt-to-Equity Related Terms
Savior Lifetec Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Savior Lifetec's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4167 vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Savior Lifetec's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Savior Lifetec Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Savior Lifetec's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Savior Lifetec's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Savior Lifetec (ROCO:4167) has a Debt-to-Equity of 0.07 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Savior Lifetec and its competitors. This is 76% below median its historical median of 0.29. Over the past decade, Savior Lifetec's Debt-to-Equity has ranged from 0.05 to 0.90. According to the industry distribution chart, Savior Lifetec ranks #339 out of 964 companies in the Biotechnology industry, placing it in the top 35.2%.
Is Savior Lifetec's Debt-to-Equity too high?
Savior Lifetec's current Debt-to-Equity of 0.07 is 76% below median its 10-year median of 0.29. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 0.90. The Biotechnology industry median Debt-to-Equity is 0.16. Savior Lifetec's value of 0.07 is 54.8% below this industry median. Based on the distribution chart, Savior Lifetec ranks #339 out of 964 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Savior Lifetec has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Savior Lifetec's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Savior Lifetec ranks #339 out of 964 companies for Debt-to-Equity. This puts Savior Lifetec in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Savior Lifetec's value of 0.07 is 54.8% below this benchmark. Historically, Savior Lifetec's own Debt-to-Equity has ranged from 0.05 to 0.90 over the past decade. While the company's 10-year median is 0.29 vs. the industry median of 0.16, Savior Lifetec has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Savior Lifetec's current Debt-to-Equity of 0.07 is 54.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Savior Lifetec and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Savior Lifetec's current Debt-to-Equity is 0.07, which is 76% below median its own 10-year median of 0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Savior Lifetec stock overvalued right now?
Based on GuruFocus' analysis, Savior Lifetec (ROCO:4167) is currently considered Fairly Valued. The stock's GF Value™ is NT$18.12, compared to a current price of NT$19.75 — trading 9% above its estimated fair value. The current Debt-to-Equity is 0.07, which is 76% below median its 10-year median of 0.29 and 54.8% below the Biotechnology industry median of 0.16. Savior Lifetec's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Savior Lifetec (ROCO:4167), the current Debt-to-Equity is 0.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Savior Lifetec (ROCO:4167) Overvalued in 2026?
Based on GuruFocus' analysis, Savior Lifetec stock appears to be overvalued.
The current stock price of NT$19.75 is trading 9% above its estimated GF Value™ of NT$18.12.
GuruFocus considers Savior Lifetec to be Fairly Valued.
Key valuation signals for ROCO:4167:
Debt-to-Equity: 0.07 (76% below median its 10-year median of 0.29)
GF Value™: NT$18.12 vs. price of NT$19.75 (9% above fair value)
Industry Position: 54.8% below the Biotechnology median (#339 of 964)
No single metric tells the full story. See the ROCO:4167 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Savior Lifetec Corp is engaged in the research, development, design, manufacture, and sale of carbapenem generics, injection generics, controlled-release generics, development of new dosage forms and drugs, and the APIs, excipients, intermediates, and dosage forms of the aforementioned products. The company also provides medicine manufacturer technology and services. The company geographically operates in four regions: the Americas, Asia, Taiwan, and Europe.
70GF Score
Get the complete analysis for ROCO:4167
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4167 has been successfully added to your 
